Want to see PASG full AI Analyst Report?
PASG Stock Chart & Stats
$11.67
>-$0.01(-0.86%)
At close: 4:00 PM EST
$11.67
>-$0.01(-0.86%)
Day’s Range― - ―
52-Week Range$3.29 - $20.00
Previous CloseN/A
Volume182.24K
Average Volume (3M)41.18K
Market Cap
$14.68M
Enterprise Value-$10.48M
Total Cash (Recent Filing)$33.34M
Total Debt (Recent Filing)$5.75M
Price to Earnings (P/E)―
Beta2.19
Next Earnings
Jul 30, 2026EPS Estimate
-2.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.85
Shares Outstanding3,212,810
10 Day Avg. Volume55,130
30 Day Avg. Volume41,182
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio-1.19
Enterprise Value/Market Cap-0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit31.86
Enterprise Value/Ebitda0.31
Forecast
1Y Price Target
$11.75Price Target Upside0.69% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)-10.3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Deleveraging / Lower DebtA meaningful decline in absolute debt materially reduces financial obligations and interest sensitivity. Lower leverage improves flexibility to fund clinical programs or pursue partnerships with less near-term refinancing risk, strengthening the firm's resilience over the next several quarters.
Improving Loss TrendA prolonged narrowing of net losses reflects durable cost control and reduced operating burn. This trend lengthens the time the company can sustain R&D activity per unit of financing, improving odds of reaching clinical inflection points without immediate, large-scale capital raises.
Merger And Secured Financing Improves RunwayThe Remix merger plus $100M committed financing is a structural capital event that extends operational runway into 2028 and concentrates leadership and resources on programs with upcoming readouts. That capital-backed runway materially raises the probability of reaching value-driving milestones.
Bears Say
Pre-revenue Business ModelWith no product revenue, the firm remains fully dependent on external financing or partnerships to sustain operations. Persistent negative operating and free cash flow creates structural dilution risk and makes the company vulnerable to financing market cycles or clinical setbacks over the medium term.
Sharply Reduced Equity CushionA collapsing equity base limits the company’s ability to absorb losses and reduces financial flexibility. Lower shareholders’ equity increases reliance on dilutive financing, weakens negotiation leverage in deals, and heightens the structural risk that further capital raises will significantly dilute existing holders.
Operational And Pipeline Uncertainty From PivotThe strategic pivot that winds down core gene therapy activities, returns program rights, and shifts control introduces durable uncertainty about which assets will be developed. Workforce cuts, program returns, and contract terminations can slow or erase prior R&D progress and complicate value realization for remaining assets.
Passage Bio News
PASG FAQ
What was Passage Bio’s price range in the past 12 months?
Passage Bio lowest stock price was $3.29 and its highest was $20.00 in the past 12 months.
What is Passage Bio’s market cap?
Passage Bio’s market cap is $14.68M.
When is Passage Bio’s upcoming earnings report date?
Passage Bio’s upcoming earnings report date is Jul 30, 2026 which is in 17 days.
How were Passage Bio’s earnings last quarter?
Passage Bio released its earnings results on May 19, 2026. The company reported -$2.84 earnings per share for the quarter, missing the consensus estimate of -$2.764 by -$0.076.
Is Passage Bio overvalued?
According to Wall Street analysts Passage Bio’s price is currently Undervalued.
Does Passage Bio pay dividends?
Passage Bio does not currently pay dividends.
What is Passage Bio’s EPS estimate?
Passage Bio’s EPS estimate is -2.65.
How many shares outstanding does Passage Bio have?
Passage Bio has 3,212,810 shares outstanding.
What happened to Passage Bio’s price movement after its last earnings report?
Passage Bio reported an EPS of -$2.84 in its last earnings report, missing expectations of -$2.764. Following the earnings report the stock price went down -0.781%.
Which hedge fund is a major shareholder of Passage Bio?
Currently, no hedge funds are holding shares in PASG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Passage Bio
Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues. Another key program, PBFT02, employs an AAV1 capsid to introduce a functional granulin (GRN) gene, encoding progranulin (PGRN), to the brain as a treatment for FTD-GRN. Additionally, PBKR03 is under development for infantile Krabbe disease, leveraging a proprietary AAVhu68 capsid to deliver a functional GALC gene, responsible for producing the hydrolytic enzyme galactosylceramidase, to the brain and surrounding tissues. The company's portfolio also features PBML04 for metachromatic leukodystrophy, PBAL05 for amyotrophic lateral sclerosis, and PBCM06 for Charcot-Marie-Tooth Type 2A. Passage Bio maintains a significant research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program, alongside a development services and clinical supply agreement with Catalent Maryland, Inc. Established in 2017, the company's headquarters are located in Philadelphia, Pennsylvania.
PASG Stock 12 Month Forecast
Average Price Target
$11.75
▲(0.69% Upside)
Technical Analysis
Tempest Therapeutics
―
Chemomab Therapeutics
―
Annovis Bio
―
―
Cognition Therapeutics
―
Ownership Overview
21.93% Insiders
5.50% Mutual Funds
41.91% Other Institutional Investors
27.05% Public Companies and
Individual Investors